News >

Expert Weighs Treatment Methods in Hodgkin Lymphoma

Caroline Seymour
Published: Tuesday, May 22, 2018

Nilanjan Ghosh, MD, PhD

Nilanjan Ghosh, MD, PhD
PET-adapted therapy has been incorporated for the last 5 to 7 years in Hodgkin lymphoma, says Nilanjan Ghosh, MD, PhD, a physician at Levine Cancer Institute.

on Hematologic Malignancies, Ghosh discussed the advances and ongoing research in frontline treatment of patients with Hodgkin lymphoma.

OncLive: Please provide an overview of your presentation.

Ghosh: I spoke about the frontline treatment of early-stage and advanced-stage Hodgkin lymphoma. I presented some of the data about PET-adapted treatment in newly diagnosed Hodgkin lymphoma, as well as the introduction of brentuximab vedotin (Adcetris) with adriamycin, vinblastine, and dacarbazine (AVD). Brentuximab vedotin with AVD is a non-PET–adapted treatment and has been recently FDA approved in the frontline treatment of patients with stage III and IV Hodgkin lymphoma.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication